AIM: We aimed to evaluate the usefulness of FDG PET in the early prediction of the effects of chemotherapy on human testicular cancer xenografts. MATERIAL AND METHODS: Nude rats bearing subcutaneous human embryonal carcinoma xenografts received either cisplatin (5 mg/kg) or saline serum. Small-animal PET studies were performed on days 0, 2, 4 and 7 and compared to immunochemistry studies, flow cytometry studies and hexokinase assays. RESULTS: Cisplatin treatment resulted in biphasic FDG uptake evolution: a peak was observed on day 2, followed by a marked decrease on day 7 despite an insignificant change in tumour volume. Similarly, a peak in cyclin A immunostaining was observed on days 2 and 4), followed by a significant decrease on day 7. Flow cytometry showed that the cyclin A peak was not related to increased cell proliferation but was due to a transient S and G(2)/M cell cycle arrest. A marked increase in cell apoptosis was observed from day 2 to day 7. GLUT-1 showed a significant decrease on day 7. Macrophagic infiltrate remained stable except for an increase observed on day 7. In control tumours, continuous growth was observed, all immunostaining markers remaining stable over time. Hexokinase activity was significantly lower on day 7 in treated tumours than in controls. CONCLUSION: FDG PET may be useful in the early evaluation of treatment in patients with testicular cancer. In our model, a very early increased [(18)F]-FDG uptake was related to a transient cell cycle arrest and early stage apoptosis but did not reveal refractory disease.
AIM: We aimed to evaluate the usefulness of FDG PET in the early prediction of the effects of chemotherapy on humantesticular cancer xenografts. MATERIAL AND METHODS: Nude rats bearing subcutaneous humanembryonal carcinoma xenografts received either cisplatin (5 mg/kg) or saline serum. Small-animal PET studies were performed on days 0, 2, 4 and 7 and compared to immunochemistry studies, flow cytometry studies and hexokinase assays. RESULTS:Cisplatin treatment resulted in biphasic FDG uptake evolution: a peak was observed on day 2, followed by a marked decrease on day 7 despite an insignificant change in tumour volume. Similarly, a peak in cyclin A immunostaining was observed on days 2 and 4), followed by a significant decrease on day 7. Flow cytometry showed that the cyclin A peak was not related to increased cell proliferation but was due to a transient S and G(2)/M cell cycle arrest. A marked increase in cell apoptosis was observed from day 2 to day 7. GLUT-1 showed a significant decrease on day 7. Macrophagic infiltrate remained stable except for an increase observed on day 7. In control tumours, continuous growth was observed, all immunostaining markers remaining stable over time. Hexokinase activity was significantly lower on day 7 in treated tumours than in controls. CONCLUSION: FDG PET may be useful in the early evaluation of treatment in patients with testicular cancer. In our model, a very early increased [(18)F]-FDG uptake was related to a transient cell cycle arrest and early stage apoptosis but did not reveal refractory disease.
Authors: U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf Journal: Eur J Nucl Med Date: 2001-04
Authors: Giovanni L Ceresoli; Arturo Chiti; Paolo A Zucali; Marcello Rodari; Romano F Lutman; Silvia Salamina; Matteo Incarbone; Marco Alloisio; Armando Santoro Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Carleen Cullinane; Donna S Dorow; Maya Kansara; Nelly Conus; David Binns; Rodney J Hicks; Leonie K Ashman; Grant A McArthur; David M Thomas Journal: Cancer Res Date: 2005-11-01 Impact factor: 12.701
Authors: Melissa L Fishel; Ying He; April M Reed; Helen Chin-Sinex; Gary D Hutchins; Marc S Mendonca; Mark R Kelley Journal: DNA Repair (Amst) Date: 2007-10-31
Authors: Rosa F Hwang; Kenji Yokoi; Corazon D Bucana; Rachel Tsan; Jerald J Killion; Douglas B Evans; Isaiah J Fidler Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: C Bokemeyer; C Kollmannsberger; K Oechsle; B M Dohmen; A Pfannenberg; C D Claussen; R Bares; L Kanz Journal: Br J Cancer Date: 2002-02-12 Impact factor: 7.640
Authors: Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo Journal: Mol Imaging Biol Date: 2012-10 Impact factor: 3.488
Authors: Lieselot Brepoels; Marijke De Saint-Hubert; Sigrid Stroobants; Gregor Verhoef; Jan Balzarini; Luc Mortelmans; Felix M Mottaghy Journal: Eur J Nucl Med Mol Imaging Date: 2010-05-12 Impact factor: 9.236
Authors: Darren Roblyer; Shigeto Ueda; Albert Cerussi; Wendy Tanamai; Amanda Durkin; Rita Mehta; David Hsiang; John A Butler; Christine McLaren; Wen-Pin Chen; Bruce Tromberg Journal: Proc Natl Acad Sci U S A Date: 2011-08-18 Impact factor: 11.205
Authors: Seth T Gammon; Brian J Engel; Gregory J Gores; Erik Cressman; David Piwnica-Worms; Steven W Millward Journal: Mol Imaging Biol Date: 2020-10 Impact factor: 3.488
Authors: Marijke De Saint-Hubert; Lieselot Brepoels; Ellen Devos; Peter Vermaelen; Tjibe De Groot; Thomas Tousseyn; Luc Mortelmans; Felix M Mottaghy Journal: Am J Nucl Med Mol Imaging Date: 2011-12-15